Tigecycline is NOT recommended for urinary tract infections
Tigecycline should not be used for UTI treatment. The FDA-approved indications for tigecycline explicitly exclude urinary tract infections, and the drug achieves inadequate urinary concentrations for effective treatment 1.
Why Tigecycline Fails for UTI
The FDA label clearly states tigecycline is approved only for:
- Complicated skin and skin structure infections
- Complicated intra-abdominal infections
- Community-acquired bacterial pneumonia
Tigecycline is NOT indicated for UTI because it undergoes primarily biliary/fecal excretion (59%) with only 33% renal excretion, resulting in subtherapeutic urinary drug levels 2.
Standard Dosing (When Used for Approved Indications)
For FDA-approved indications only 1:
- Loading dose: 100 mg IV once
- Maintenance: 50 mg IV every 12 hours
- Infusion time: 30-60 minutes
- Duration: 5-14 days depending on infection site
Renal Function Adjustments
No dose adjustment needed for renal impairment - including severe renal failure or hemodialysis 1, 3. Tigecycline clearance decreases only ~20% even in severe renal impairment, and the drug is not removed by dialysis 3.
Hepatic Function Adjustments
- Mild-moderate impairment (Child-Pugh A-B): No adjustment needed
- Severe impairment (Child-Pugh C): Reduce maintenance to 25 mg IV every 12 hours (keep 100 mg loading dose) 1
Critical Safety Concerns
Black Box Warning: Tigecycline carries increased all-cause mortality (0.6% absolute increase, 95% CI 0.1-1.2%) compared to comparators 1. Reserve use only when alternative treatments are unsuitable.
If Multidrug-Resistant UTI Requires Tigecycline
When tigecycline is the only susceptible agent for MDR organisms causing UTI (extremely rare scenario):
For Carbapenem-Resistant Enterobacterales (CRE) UTI
Preferred alternatives exist 4:
- Ceftazidime-avibactam 2.5 g IV q8h (first choice)
- Meropenem-vaborbactam 4 g IV q8h
- Imipenem-cilastatin-relebactam 1.25 g IV q6h
- Plazomicin 15 mg/kg IV q12h
- Single-dose aminoglycosides for simple cystitis
For VRE UTI
Better options available 4:
- Uncomplicated UTI: Fosfomycin 3 g PO single dose, nitrofurantoin 100 mg PO q6h, or high-dose ampicillin
- Complicated UTI: Linezolid 600 mg IV/PO q12h or daptomycin 6-12 mg/kg IV daily
Last-Resort Tigecycline Use for UTI
If absolutely no alternatives exist 5, 6:
- Use standard dosing: 100 mg loading, then 50 mg IV q12h
- Case reports show 88.9% favorable response in MDR UTI 5
- Median duration: 13 days (range 10-15 days)
- Monitor closely for recurrence (occurred in 4/24 responders within 3 months) 5
- Consider combination therapy rather than monotherapy
Common Pitfalls
- Do not use tigecycline as first-line for any UTI - poor urinary penetration makes it inherently suboptimal
- Do not adjust dose for renal failure - this is a common error; renal function does not significantly affect tigecycline clearance
- Do reduce dose for Child-Pugh C cirrhosis - this adjustment is frequently missed
- Avoid in pediatrics - not approved for age <18 years due to mortality concerns 4
- Infectious disease consultation strongly recommended when considering tigecycline for off-label UTI use 4
The evidence consistently demonstrates that tigecycline should be reserved for its approved indications where it demonstrates efficacy. For UTI, multiple superior alternatives exist even for MDR organisms.